AI-generated analysis. Always verify with the original filing.
Absci Corporation announced the retirement of Chief Innovation Officer Andreas Busch, Ph.D., effective March 31, 2026, with transition to scientific advisor role, and appointment of Ransi Somaratne, M.D., as Chief Medical Officer effective March 3, 2026. The Board approved amended and restated director and officer indemnification agreements on March 6, 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
above is incorporated in this Item 5.02 by reference. Item 7.01 Regulation FD Disclosures. On March 3, 2026, the Company issued a press release announcing Dr. B
. D eparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On March 3,
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Sec
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Form of Director Indemnification Agreement, as adopted on March 6, 2026 10.2 Form
Andreas Busch, Ph.D.
Effective: 2026-03-31
Retirement; no disagreement with Company operations, policies or practices
Ransi Somaratne, M.D.
Effective: 2026-03-03
Material Agreement